Matches in SemOpenAlex for { <https://semopenalex.org/work/W4364296577> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4364296577 endingPage "587" @default.
- W4364296577 startingPage "579" @default.
- W4364296577 abstract "Remogliflozin and Vildagliptin are the latest drug combination in order to treat type 2 diabetes. The present work describes a comparative study of 2nd-ordered derivative UV and isocratic stability indicating RP-HPLC methods for simultaneous determination of Remogliflozin and Vildagliptin in the drug and its formulation. The HPLC method was established with a C18 column and the mobile phase with Buffer (pH-6.50): Acetonitrile: Methanol ratio of 55:44:1, at 1.2 ml/min flow and wavelength of 210 nm. The UV spectrophotometric method works on spectrophotometry with 2nd order derivative spectra(2D) using a zero-line cross method. The absorbance determination was performed at 246.0 nm for REM and at 219 .6 nm for VIL. The methods were validated for Linearity, Precision, Recovery, Robustness, and Forced degradation as per ICH-Q2(R1). The linear range was established in the range of 4-80 ppm for REM and 2-40 ppm for VIL for the UV method and 2-200 ppm for REM and 1-100 ppm for VIL for the HPLC method with regression coefficient ≥0.990. The accuracy was 99.37% & 99.62% for UV and 100.98 & 100.65 for the HPLC method for REM and VIL respectively. The proposed methods have been effectively used for the quantification of REM and VIL in API mixture and formulation dosage forms. Both methods are economical, fast, simple, and accurate which can be easily adopted for laboratory use." @default.
- W4364296577 created "2023-04-12" @default.
- W4364296577 creator A5036601346 @default.
- W4364296577 creator A5037628523 @default.
- W4364296577 creator A5040701774 @default.
- W4364296577 date "2023-01-01" @default.
- W4364296577 modified "2023-09-27" @default.
- W4364296577 title "STABILITY INDICATING ISOCRATIC RP-HPLC AND SECOND DERIVATIVE UV SPECTROSCOPIC METHODS FOR SIMULTANEOUS DETERMINATION OF REMOGLIFLOZIN ETABONATE AND VILDAGLIPTIN HYDROCHLORIDE" @default.
- W4364296577 doi "https://doi.org/10.31788/rjc.2023.1628212" @default.
- W4364296577 hasPublicationYear "2023" @default.
- W4364296577 type Work @default.
- W4364296577 citedByCount "0" @default.
- W4364296577 crossrefType "journal-article" @default.
- W4364296577 hasAuthorship W4364296577A5036601346 @default.
- W4364296577 hasAuthorship W4364296577A5037628523 @default.
- W4364296577 hasAuthorship W4364296577A5040701774 @default.
- W4364296577 hasBestOaLocation W43642965771 @default.
- W4364296577 hasConcept C106159729 @default.
- W4364296577 hasConcept C111771559 @default.
- W4364296577 hasConcept C113196181 @default.
- W4364296577 hasConcept C134018914 @default.
- W4364296577 hasConcept C134306372 @default.
- W4364296577 hasConcept C162324750 @default.
- W4364296577 hasConcept C178790620 @default.
- W4364296577 hasConcept C179998833 @default.
- W4364296577 hasConcept C185592680 @default.
- W4364296577 hasConcept C2776453732 @default.
- W4364296577 hasConcept C2777463227 @default.
- W4364296577 hasConcept C2779607525 @default.
- W4364296577 hasConcept C2780343419 @default.
- W4364296577 hasConcept C2910068830 @default.
- W4364296577 hasConcept C33257320 @default.
- W4364296577 hasConcept C33923547 @default.
- W4364296577 hasConcept C43617362 @default.
- W4364296577 hasConcept C555293320 @default.
- W4364296577 hasConcept C71924100 @default.
- W4364296577 hasConcept C77281830 @default.
- W4364296577 hasConcept C98015330 @default.
- W4364296577 hasConceptScore W4364296577C106159729 @default.
- W4364296577 hasConceptScore W4364296577C111771559 @default.
- W4364296577 hasConceptScore W4364296577C113196181 @default.
- W4364296577 hasConceptScore W4364296577C134018914 @default.
- W4364296577 hasConceptScore W4364296577C134306372 @default.
- W4364296577 hasConceptScore W4364296577C162324750 @default.
- W4364296577 hasConceptScore W4364296577C178790620 @default.
- W4364296577 hasConceptScore W4364296577C179998833 @default.
- W4364296577 hasConceptScore W4364296577C185592680 @default.
- W4364296577 hasConceptScore W4364296577C2776453732 @default.
- W4364296577 hasConceptScore W4364296577C2777463227 @default.
- W4364296577 hasConceptScore W4364296577C2779607525 @default.
- W4364296577 hasConceptScore W4364296577C2780343419 @default.
- W4364296577 hasConceptScore W4364296577C2910068830 @default.
- W4364296577 hasConceptScore W4364296577C33257320 @default.
- W4364296577 hasConceptScore W4364296577C33923547 @default.
- W4364296577 hasConceptScore W4364296577C43617362 @default.
- W4364296577 hasConceptScore W4364296577C555293320 @default.
- W4364296577 hasConceptScore W4364296577C71924100 @default.
- W4364296577 hasConceptScore W4364296577C77281830 @default.
- W4364296577 hasConceptScore W4364296577C98015330 @default.
- W4364296577 hasIssue "02" @default.
- W4364296577 hasLocation W43642965771 @default.
- W4364296577 hasOpenAccess W4364296577 @default.
- W4364296577 hasPrimaryLocation W43642965771 @default.
- W4364296577 hasRelatedWork W139793748 @default.
- W4364296577 hasRelatedWork W1976246576 @default.
- W4364296577 hasRelatedWork W1977798251 @default.
- W4364296577 hasRelatedWork W1979329085 @default.
- W4364296577 hasRelatedWork W2024637950 @default.
- W4364296577 hasRelatedWork W2046604074 @default.
- W4364296577 hasRelatedWork W2075289655 @default.
- W4364296577 hasRelatedWork W2426769554 @default.
- W4364296577 hasRelatedWork W2758599831 @default.
- W4364296577 hasRelatedWork W2560041681 @default.
- W4364296577 hasVolume "16" @default.
- W4364296577 isParatext "false" @default.
- W4364296577 isRetracted "false" @default.
- W4364296577 workType "article" @default.